RetractedArticleFrontiers in oncology2024

PARC: a phase I/II study evaluating the safety and activity of pegylated recombinant human arginase BCT-100 in relapsed/refractory cancers of children and young adults.

Nicola Fenwick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.